Rimonabant for the treatment of obesity

Area of Science:

• Pharmacology
• Endocrinology
• Public Health

Background:

• Obesity is a global epidemic affecting all age groups, with limited effective pharmacotherapeutic options.
• The endogenous cannabinoid system (ECS), discovered in the 1990s, plays a role in regulating food intake.
• CB1 receptors, targeted by antagonists, are found in the brain and peripheral tissues involved in metabolism.

Purpose of the Study:

• To review the evidence and patents related to rimonabant, a selective CB1 receptor antagonist, for obesity treatment.
• To discuss the safety concerns that have hindered rimonabant's approval and use, particularly in the US market.

Main Methods:

• Literature review of studies on the endogenous cannabinoid system and obesity.
• Analysis of regulatory approvals and withdrawals of rimonabant (SR141716).
• Examination of patents and safety data concerning rimonabant's efficacy and adverse effects.

Main Results:

• Rimonabant was approved by European authorities in 2006 for treating obesity.
• The US FDA's advisory committee recommended against rimonabant's approval in 2007 due to safety concerns.
• Potential safety issues remain a barrier to rimonabant's use in major pharmaceutical markets.

Conclusions:

• The ECS is a potential target for obesity pharmacotherapy.
• Selective CB1 receptor antagonism, exemplified by rimonabant, shows promise but faces significant safety hurdles.
• Further research is needed to develop safer and more effective obesity treatments targeting the ECS.